Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1997 Dec;41(12):2729–2732. doi: 10.1128/aac.41.12.2729

In vitro susceptibilities of the AIDS-associated microsporidian Encephalitozoon intestinalis to albendazole, its sulfoxide metabolite, and 12 additional benzimidazole derivatives.

S K Katiyar 1, T D Edlind 1
PMCID: PMC164197  PMID: 9420047

Abstract

Recent reports have described the successful treatment of Encephalitozoon intestinalis infection in AIDS patients with albendazole. However, this compound is rapidly metabolized in vivo to albendazole sulfoxide, and furthermore it is only 1 of about 15 commercially developed benzimidazole derivatives. To compare the activities of albendazole, albendazole sulfoxide, and other benzimidazoles, an in vitro system involving infection of green monkey kidney cell (E6) monolayers with E. intestinalis spores was developed. After 14 days, the effects of benzimidazoles on spore production were determined. Ten of fourteen derivatives tested, including albendazole, were inhibitory at concentrations of 1 to 10 ng/ml. Derivatives modified at the 1 or 2 position were less active. Albendazole sulfoxide was 1.7-fold more inhibitory than albendazole but significantly less toxic to E6 cells, a finding that explains the clinical efficacy of this compound. Potential alternatives to albendazole are discussed. No albendazole-resistant E. intestinalis mutants were obtained following in vitro selection.

Full Text

The Full Text of this article is available as a PDF (130.8 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aarons E. J., Woodrow D., Hollister W. S., Canning E. U., Francis N., Gazzard B. G. Reversible renal failure caused by a microsporidian infection. AIDS. 1994 Aug;8(8):1119–1121. doi: 10.1097/00002030-199408000-00013. [DOI] [PubMed] [Google Scholar]
  2. Asmuth D. M., DeGirolami P. C., Federman M., Ezratty C. R., Pleskow D. K., Desai G., Wanke C. A. Clinical features of microsporidiosis in patients with AIDS. Clin Infect Dis. 1994 May;18(5):819–825. doi: 10.1093/clinids/18.5.819. [DOI] [PubMed] [Google Scholar]
  3. Baker M. D., Vossbrinck C. R., Didier E. S., Maddox J. V., Shadduck J. A. Small subunit ribosomal DNA phylogeny of various microsporidia with emphasis on AIDS related forms. J Eukaryot Microbiol. 1995 Sep-Oct;42(5):564–570. doi: 10.1111/j.1550-7408.1995.tb05906.x. [DOI] [PubMed] [Google Scholar]
  4. Bartlett M. S., Edlind T. D., Durkin M. M., Shaw M. M., Queener S. F., Smith J. W. Antimicrotubule benzimidazoles inhibit in vitro growth of Pneumocystis carinii. Antimicrob Agents Chemother. 1992 Apr;36(4):779–782. doi: 10.1128/aac.36.4.779. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Bartlett M. S., Edlind T. D., Lee C. H., Dean R., Queener S. F., Shaw M. M., Smith J. W. Albendazole inhibits Pneumocystis carinii proliferation in inoculated immunosuppressed mice. Antimicrob Agents Chemother. 1994 Aug;38(8):1834–1837. doi: 10.1128/aac.38.8.1834. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Beauvais B., Sarfati C., Challier S., Derouin F. In vitro model to assess effect of antimicrobial agents on Encephalitozoon cuniculi. Antimicrob Agents Chemother. 1994 Oct;38(10):2440–2448. doi: 10.1128/aac.38.10.2440. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Blanshard C., Ellis D. S., Tovey D. G., Dowell S., Gazzard B. G. Treatment of intestinal microsporidiosis with albendazole in patients with AIDS. AIDS. 1992 Mar;6(3):311–313. doi: 10.1097/00002030-199203000-00009. [DOI] [PubMed] [Google Scholar]
  8. Cruz M. C., Bartlett M. S., Edlind T. D. In vitro susceptibility of the opportunistic fungus Cryptococcus neoformans to anthelmintic benzimidazoles. Antimicrob Agents Chemother. 1994 Feb;38(2):378–380. doi: 10.1128/aac.38.2.378. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. De Groote M. A., Visvesvara G., Wilson M. L., Pieniazek N. J., Slemenda S. B., daSilva A. J., Leitch G. J., Bryan R. T., Reves R. Polymerase chain reaction and culture confirmation of disseminated Encephalitozoon cuniculi in a patient with AIDS: successful therapy with albendazole. J Infect Dis. 1995 May;171(5):1375–1378. doi: 10.1093/infdis/171.5.1375. [DOI] [PubMed] [Google Scholar]
  10. Didier E. S., Rogers L. B., Orenstein J. M., Baker M. D., Vossbrinck C. R., Van Gool T., Hartskeerl R., Soave R., Beaudet L. M. Characterization of Encephalitozoon (Septata) intestinalis isolates cultured from nasal mucosa and bronchoalveolar lavage fluids of two AIDS patients. J Eukaryot Microbiol. 1996 Jan-Feb;43(1):34–43. doi: 10.1111/j.1550-7408.1996.tb02470.x. [DOI] [PubMed] [Google Scholar]
  11. Dieterich D. T., Lew E. A., Kotler D. P., Poles M. A., Orenstein J. M. Treatment with albendazole for intestinal disease due to Enterocytozoon bieneusi in patients with AIDS. J Infect Dis. 1994 Jan;169(1):178–183. doi: 10.1093/infdis/169.1.178. [DOI] [PubMed] [Google Scholar]
  12. Ditrich O., Kucerová Z., Koudela B. In vitro sensitivity of Encephalitozoon cuniculi and E. hellem to albendazole. J Eukaryot Microbiol. 1994 Sep-Oct;41(5):37S–37S. [PubMed] [Google Scholar]
  13. Franssen F. F., Lumeij J. T., van Knapen F. Susceptibility of Encephalitozoon cuniculi to several drugs in vitro. Antimicrob Agents Chemother. 1995 Jun;39(6):1265–1268. doi: 10.1128/aac.39.6.1265. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Hartskeerl R. A., Van Gool T., Schuitema A. R., Didier E. S., Terpstra W. J. Genetic and immunological characterization of the microsporidian Septata intestinalis Cali, Kotler and Orenstein, 1993: reclassification to Encephalitozoon intestinalis. Parasitology. 1995 Apr;110(Pt 3):277–285. doi: 10.1017/s0031182000080860. [DOI] [PubMed] [Google Scholar]
  15. Joste N. E., Rich J. D., Busam K. J., Schwartz D. A. Autopsy verification of Encephalitozoon intestinalis (microsporidiosis) eradication following albendazole therapy. Arch Pathol Lab Med. 1996 Feb;120(2):199–203. [PubMed] [Google Scholar]
  16. Kamaishi T., Hashimoto T., Nakamura Y., Nakamura F., Murata S., Okada N., Okamoto K., Shimizu M., Hasegawa M. Protein phylogeny of translation elongation factor EF-1 alpha suggests microsporidians are extremely ancient eukaryotes. J Mol Evol. 1996 Feb;42(2):257–263. doi: 10.1007/BF02198852. [DOI] [PubMed] [Google Scholar]
  17. Katiyar S. K., Gordon V. R., McLaughlin G. L., Edlind T. D. Antiprotozoal activities of benzimidazoles and correlations with beta-tubulin sequence. Antimicrob Agents Chemother. 1994 Sep;38(9):2086–2090. doi: 10.1128/aac.38.9.2086. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Keeling P. J., Doolittle W. F. Alpha-tubulin from early-diverging eukaryotic lineages and the evolution of the tubulin family. Mol Biol Evol. 1996 Dec;13(10):1297–1305. doi: 10.1093/oxfordjournals.molbev.a025576. [DOI] [PubMed] [Google Scholar]
  19. Lacey E. The role of the cytoskeletal protein, tubulin, in the mode of action and mechanism of drug resistance to benzimidazoles. Int J Parasitol. 1988 Nov;18(7):885–936. doi: 10.1016/0020-7519(88)90175-0. [DOI] [PubMed] [Google Scholar]
  20. Li J., Katiyar S. K., Edlind T. D. Site-directed mutagenesis of Saccharomyces cerevisiae beta-tubulin: interaction between residue 167 and benzimidazole compounds. FEBS Lett. 1996 Apr 29;385(1-2):7–10. doi: 10.1016/0014-5793(96)00334-1. [DOI] [PubMed] [Google Scholar]
  21. Li J., Katiyar S. K., Hamelin A., Visvesvara G. S., Edlind T. D. Tubulin genes from AIDS-associated microsporidia and implications for phylogeny and benzimidazole sensitivity. Mol Biochem Parasitol. 1996 Jun;78(1-2):289–295. doi: 10.1016/s0166-6851(96)02628-x. [DOI] [PubMed] [Google Scholar]
  22. Molina J. M., Oksenhendler E., Beauvais B., Sarfati C., Jaccard A., Derouin F., Modaï J. Disseminated microsporidiosis due to Septata intestinalis in patients with AIDS: clinical features and response to albendazole therapy. J Infect Dis. 1995 Jan;171(1):245–249. doi: 10.1093/infdis/171.1.245. [DOI] [PubMed] [Google Scholar]
  23. Van den Bossche H., Rochette F., Hörig C. Mebendazole and related anthelmintics. Adv Pharmacol Chemother. 1982;19:67–128. doi: 10.1016/s1054-3589(08)60021-6. [DOI] [PubMed] [Google Scholar]
  24. Visvesvara G. S., da Silva A. J., Croppo G. P., Pieniazek N. J., Leitch G. J., Ferguson D., de Moura H., Wallace S., Slemenda S. B., Tyrrell I. In vitro culture and serologic and molecular identification of Septata intestinalis isolated from urine of a patient with AIDS. J Clin Microbiol. 1995 Apr;33(4):930–936. doi: 10.1128/jcm.33.4.930-936.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Vossbrinck C. R., Maddox J. V., Friedman S., Debrunner-Vossbrinck B. A., Woese C. R. Ribosomal RNA sequence suggests microsporidia are extremely ancient eukaryotes. 1987 Mar 26-Apr 1Nature. 326(6111):411–414. doi: 10.1038/326411a0. [DOI] [PubMed] [Google Scholar]
  26. Weber R., Bryan R. T., Schwartz D. A., Owen R. L. Human microsporidial infections. Clin Microbiol Rev. 1994 Oct;7(4):426–461. doi: 10.1128/cmr.7.4.426. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Weber R., Sauer B., Spycher M. A., Deplazes P., Keller R., Ammann R., Briner J., Lüthy R. Detection of Septata intestinalis in stool specimens and coprodiagnostic monitoring of successful treatment with albendazole. Clin Infect Dis. 1994 Aug;19(2):342–345. doi: 10.1093/clinids/19.2.342. [DOI] [PubMed] [Google Scholar]
  28. van Gool T., Canning E. U., Gilis H., van den Bergh Weerman M. A., Eeftinck Schattenkerk J. K., Dankert J. Septata intestinalis frequently isolated from stool of AIDS patients with a new cultivation method. Parasitology. 1994 Sep;109(Pt 3):281–289. doi: 10.1017/s0031182000078318. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES